###begin article-title 0
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 96 104 <span type="species:ncbi:9606">children</span>
HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia
###end article-title 0
###begin p 1
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
###xml 1147 1155 <span type="species:ncbi:9606">Patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
###xml 1327 1335 <span type="species:ncbi:9606">patients</span>
###xml 1434 1442 <span type="species:ncbi:9606">patients</span>
Genetic control of immune reactions has a major role in the development of rheumatic heart disease (RHD) and differs between patients with rheumatic fever (RF). Some authors think the risk of acquiring RHD is associated with the HLA class II DR and DQ loci, but other views exist, due to the various HLA-typing methods and ways of grouping cases. Our goal was to determine the relations between HLA class II alleles and risk of or protection from RF in patients with relatively homogeneous clinical manifestations. A total of 70 RF patients under the age of 18 years were surveyed in Latvia. HLA genotyping of DRB1*01 to DRB1*18 and DQB1*0201-202, *0301-305, *0401-402, *0501-504, and *0601-608 was performed using polymerase chain reaction sequence-specific primers. Data for a control group of 100 healthy individuals typed for HLA by the same method were available from the databank of the Immunology Institute of Latvia. Of the RF patients, 47 had RHD and 8 had Sydenham's chorea. We concluded that HLA class II DRB1*07-DQB1*0401-2 and DRB1*07-DQB1*0302 could be the risk alleles and HLA class II DRB1*06 and DQB1*0602-8, the protective ones. Patients with mitral valve regurgitation more often had DRB1*07 and DQB1*0401-2, and patients with multivalvular lesions more often had DRB1*07 and DQB1*0302. In Sydenham's chorea patients, the DQB1*0401-2 allele was more frequent. Genotyping control showed a high risk of RF and RHD in patients with DRB1*01-DQB1*0301-DRB1*07-DQB1*0302 and DRB1*15-DQB1*0302-DRB1*07-DQB1*0303.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 53 60 <span type="species:ncbi:9606">Patient</span>
###xml 76 84 <span type="species:ncbi:9606">children</span>
###xml 694 702 <span type="species:ncbi:9606">children</span>
###xml 844 852 <span type="species:ncbi:9606">children</span>
According to data from the Latvian Rheumatic Disease Patient Registry, 1298 children (born between 1984 and 2002) suffer from rheumatic diseases, of which rheumatic fever (RF) is the third most frequent. RF is an autoimmune connective tissue disease that develops after group A beta haemolytic streptococcal infection. The typical feature of the disease is the formation of autoantibodies against the connective tissue structures in the heart, synovial tissue, and neurons in the central nervous system. Rheumatic heart disease (RHD) is one of the most severe consequences of RF and is the main cause of acquired valvular RHD in the world [1-9]. In Latvia, since 1991 the number of RF cases in children under the age of 18 has increased, reaching an incidence of 7.5/100,000 in 1998. From 1999 to 2002, the incidence was stable, at 2.1/100,000 children.
###end p 3
###begin p 4
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
Several authors have documented the familial occurrence of the disease [10-12], and it has been concluded that susceptibility to RF is inherited as a single recessive gene [13]. More substantial evidence for a genetic association was provided by Khanna and associates, who reported that B-cell alloantigens, designated D8-17, were present in 99% of patients with RF [13]. Further support for the role of genetic factors in susceptibility was provided by studies on the associations of this disease with inheritance of the HLA major histocompatibility antigens [14-23]. Several studies have suggested that genetic susceptibility to RF and RHD is linked to HLA class II alleles [20,24-34].
###end p 4
###begin p 5
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
However, there has been an apparent discrepancy concerning the nature of susceptibility or protective alleles [27]. One explanation is that most investigations used serological HLA genotyping methods that were less than accurate, leading to false results and failure to discriminate between allele subgroups.
###end p 5
###begin p 6
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
Genetic associations are more likely to be detected in clinically homogeneous groups of patients, and therefore it is important to separate carditis patients from patients without carditis [27]. In studies in which RF patients with carditis were analysed separately from those without carditis, or in which only RHD patients mostly with mitral valve disease were studied, the reported HLA associations were rather similar [20,25-28,34,35].
###end p 6
###begin p 7
###xml 44 52 <span type="species:ncbi:9606">children</span>
###xml 292 299 <span type="species:ncbi:9606">patient</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
We analysed the case histories of all white children under 18 years of age living in Latvia who had been affected by RF, with the aim to determine risk/protective alleles for RF and RHD. The HLA class II alleles were determined using polymerase chain reaction (PCR) in clinically homogeneous patient groups: RF patients with or without carditis and in patients with a diagnosis of an RHD - mitral valve regurgitation (MVR), mitral and aortal valve regurgitation or multivalvular lesion (MVL), and aortal valve regurgitation (AVR), and also cases of Sydenham's chorea.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Subjects
###end title 9
###begin p 10
###xml 525 527 525 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 546 548 546 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 582 584 582 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 814 816 814 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 28 36 <span type="species:ncbi:9606">children</span>
###xml 41 45 <span type="species:ncbi:9606">boys</span>
###xml 61 66 <span type="species:ncbi:9606">girls</span>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
###xml 713 721 <span type="species:ncbi:9606">patients</span>
###xml 1002 1010 <span type="species:ncbi:9606">patients</span>
The study included 70 white children (48 boys [68.5%] and 22 girls [31.4%]) in Latvia under the age of 18 (born between 1984 and 2002) who had RF. Of these, 23 (32.8%) were less than 7 years old and 47 (67.1%) were 7 or older. The RF diagnosis was confirmed according to Jones criteria. Eight RF patients had Sydenham's chorea. As a result of RF, 47 patients (67.1%) had developed RHD. Cardiac valve damage was diagnosed by echocardiography and/or heart catheterisation. RHD patients were further split into groups with MVR (n = 24; 34.3%), AVR (n = 3; 4.3%), and MVR + AVR or MVL (n = 20; 28.6%). Only 23 of the patients (32.8%) had fully recovered by the age of 18. Recurrence of RF was recorded for 15% of the patients because they had not received prolonged penicillin treatment. Data for healthy individuals (n = 100) were obtained from the Databank of the Immunology Institute of Latvia. The control individuals were free of autoimmune disease and had no family history of RF. In both groups (RF patients and healthy individuals), HLA class II alleles were determined by PCR.
###end p 10
###begin title 11
DNA isolation
###end title 11
###begin p 12
###xml 189 191 189 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 411 413 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
Genomic DNA was extracted from proteinase-K-treated peripheral blood leukocytes using the routine salt-off method. The DNA was stored in TE buffer (10 ml Tris-HCl, pH 7.5, and 2 ml 0.5 M Na2 EDTA per litre of distilled water). The DNA obtained was used immediately for genotyping or was stored at -20degreesC. The DNA concentration, around 100-200 mug/ml, was determined by fluorescence with a DNA fluorimeter [36].
###end p 12
###begin title 13
HLA-DR and -DQ genotyping by PCR
###end title 13
###begin p 14
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 297 298 294 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 410 414 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Low-resolution HLA-DR typing for DRB1* 01 to 18 and for DQB1*0201-202, *0301-305, *0401-402, *0501-504, and *0601-608 was performed by PCR with amplification with sequence-specific primers (PCR-SSP) [37]. The reaction mixture (15 mul) included 1 mul DNA, 1.5 mul PCR buffer [50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl, (pH 8.3)], 0.6 mul dNTPs (25 mmol/l), 1.0 mul specific primers (0.2 mmol/l), and 0.5 U of the Taq DNA polymerase (Promega). In addition, the internal positive control primer pair C3 and C5 was included in all reaction mixtures at a concentration one-fifth that of the allele- and group-specific primers.
###end p 14
###begin p 15
###xml 702 704 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 705 707 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 708 710 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
The reaction mixture was subjected to 35 amplification cycles, each consisting of denaturation at 94degreesC (60 s), followed by one cycle, annealing at 94degreesC (20 s), 67degreesC (2 s) followed by seven cycles and extension at 93degreesC (5 s), 65degreesC (4 s), with a final extension in step with 28 cycles. PCR products were visualized by agarose-gel electrophoresis. After addition of 2 M loading buffer, the PCR reaction mixtures were loaded in agarose gels prestained with ethidium bromide (0.5 muk/ml gel). Gels were run for 15 min at 10 V/cm gel in 0.5 mM TBE (0.89 M Tris, 0.89 M Boric acid and 0.02 M EDTA in aqueous solution) buffer and then examined under UV illumination and recorded [15,38-40].
###end p 15
###begin title 16
Statistical
###end title 16
###begin p 17
###xml 142 144 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
The HLA-DRB1 and DQB1 frequency of each allele and genotype was compared between the patients and the controls using the chi-square test. The P value and odds ratio (OR) were calculated using EPI INFO software, version 06, with 95% confidence intervals and Fisher exact correction for small numbers [41].
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Frequencies of DRB1* and DQB1* alleles in RF patients and control subjects
###end title 19
###begin p 20
###xml 49 51 49 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 82 84 82 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 227 229 227 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 263 265 263 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 302 304 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
In RF patients, HLA class II DRB1*07 (OR = 4.18, P < 0.01), DQB1*0302 (OR = 3.13, P < 0.0002), and DQB1*0401-2 (OR = 4.33, P < 0.0001) alleles were found more frequently than in the control group, while the DRB1*06 (OR = 0.18, P < 0.0023), DQB1*0602-8 (OR = 0.4, P < 0.0127), and DQB1*0501 (OR = 0.26, P < 0.0027) alleles were less frequent (Tables 1 and 2).
###end p 20
###begin title 21
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Frequencies of DRB1 and DQB1 alleles in RF, RHD, and Sydenham's chorea patients compared with control subjects
###end title 21
###begin p 22
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 180 182 180 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 479 481 479 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 548 550 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 661 663 661 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 19 26 <span type="species:ncbi:9606">patient</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
###xml 607 615 <span type="species:ncbi:9606">patients</span>
In the homogeneous patient groups, DRB1*07 had the highest OR in all RF groups (Table 3): patients with no acquired valvular heart disease developing after RF carditis (OR = 7.35, P < 0.001), MVR patients (OR = 4.45, P < 0.03), MVL patients (OR = 5.44, P < 0.01), and Sydenham's chorea patients (OR = 11.31, P < 0.002). The least frequent allele was DRB1*06 (OR = 0.18, P < 0.0023). The DQB1 allele frequencies differed for RHD patients with MVR and MVL: DQB1*0401-2 (OR = 8.20, P < 0.001) was more common in MVR patients and DQB1*0302 (OR = 4.18, P < 0.001) in MVL patients (Table 3). In Sydenham's chorea patients, a high frequency of DQB1*0401-2 (OR = 6.36, P < 0.005) was found.
###end p 22
###begin title 23
###xml 45 53 <span type="species:ncbi:9606">patients</span>
DRB1* and DQB1* genotypes associated with RF patients
###end title 23
###begin p 24
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
The strongest associations between DRB1* alleles and RF patients were for DRB1*01-07 (OR = 8.57, P < 0.05), DRB1*15-07 (OR = 2.86, P < 0.02), DRB1*04-05 (OR = 3.57, P < 0.04), and DRB1*05-07 (OR = 2.86, P < 0.02) (Table 4). The DRB1*03-06 allele (OR = 0.48, P < 0.01) had the lowest OR.
###end p 24
###begin p 25
###xml 66 68 66 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 104 106 104 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 142 144 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 186 188 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 301 303 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 345 347 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
Common alleles associated with RF are: DQB1*0301-0302 (OR = 5.44, P < 0.05), DQB1*0302-0303 (OR = 4.43, P < 0.02), DQB1*0302-0601 (OR = 2.91, P < 0.01), and DQB1*0302-0602-8 (OR = 2.19, P < 0.01) (Table 5). The lowest allele frequencies in RF patients were observed for DQB1*0201-2-0201-2 (OR = 0.28, P < 0.001) and DQB1*0303-0602-8 (OR = 0.22, P < 0.01).
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
###xml 423 430 <span type="species:ncbi:9606">patient</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
###xml 577 584 <span type="species:ncbi:9606">patient</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
HLA associations with RF and RHD have been frequently investigated, but there is no unanimity of opinion about the association of specific alleles in connection with the disease [20,32,33,35]. One reason for this discrepancy might be the use of old HLA genotyping methods [27]. Besides the technical issues, it has also been suggested that it is necessary to distinguish clinically homogeneous patient groups, for example, patient groups with and without rheumatic carditis, proved RHD, or Sydenham's chorea [27,33]. When patients have been divided into clinically homogeneous patient groups, no differences between ethnic groups have been found, with the DRB1*0701, DRB1*0301, and DQB1*0201 alleles being found at similar frequencies [18,21,32,42,43]. In medical publications, there is no unanimity of opinion about whether HLA class II alleles differ with the ethnic origin of the patients, but this may be connected to the use of different methods of typing HLA alleles.
###end p 27
###begin p 28
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 121 128 <span type="species:ncbi:9606">patient</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
The data in our investigations were obtained by investigating RF and RHD patients classified into clinically homogeneous patient groups. We found that the HLA class II DRB1*07, DQB1*0401-2, and DQB1*0302 alleles were risk factors for acquiring RF and RHD. The DRB1*07 allele was common and had a comparatively high frequency of incidence in patients with RF (Tables 1 and 3). This suggests that DRB1*07 could be a risk allele for RF and RHD. Our data on the high frequency of DRB1*07 in white patients differs from data on Brazilian patients, where HLA-DR7 was detected in the mulatto group of patients [20,44]. In our study, the HLA II allele DRB1*07 was rather frequent in white RF patients, both with and without permanent acquired valvular heart disease.
###end p 28
###begin p 29
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
The HLA class II allele DQB1*0401-2 was found more often in MVR patients, and DQB1*0302 in MVL patients. Thus, it can be assumed that HLA-DQ genes control the risk of development of RHD, both MVL and MVR. This observation confirms previous findings for RHD patients in Japan [32]. Our data obtained using the PCR-SSP method suggests that a risk of developing RHD exists for the carrier DQ allele exists in Brazil and Japan, as well as in Latvia.
###end p 29
###begin p 30
###xml 97 104 <span type="species:ncbi:9606">patient</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
However, both the DQB1*0401-2 and *0302 allele frequencies were significantly elevated in the RF patient group and in patients who did not develop permanent valvular heart disease.
###end p 30
###begin p 31
The genotyping showed that a high risk of acquiring RF and developing RHD was associated with DRB1*01-DQB1*0301-DRB1*07-DQB1*0302 and DRB1*15-DQB1*0302-DRB1*07-DQB1*0303. This, however, is only a supposition, and further experiments with a larger group will be necessary to establish whether it is correct.
###end p 31
###begin p 32
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
Protective HLA class II alleles are as important as the risk alleles. Alleles that can be designated protective include DRB1*03-*06, DQB1*0201-2-*0201-2, and DQB1*0303-*0602-8. Higher protection against RF and RHD is provided by the allele genotype DRB1*06-DQB1*0602-8 (Table 6).
###end p 32
###begin p 33
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
Among the alleles found to be protective in our study, DQB1*0602-8 is most often mentioned in the literature [20,26,27,29]. Several risk/protective HLA class II suballeles can be misperceived as other suballeles not connected with RF and RHD. Therefore it is important to determine genotypes [45-47].
###end p 33
###begin p 34
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
HLA alleles regulate the immune response to infections [48,49], binding and presenting autoantigens with different affinities and regulating selection of T cells, and at the same time they themselves can serve as target autoantigens [50-52]. Different autoimmune peptide presentations with protective or risk alleles are very important in the development and research of the pathogenesis of autoimmunity.
###end p 34
###begin p 35
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 199 220 <span type="species:ncbi:36470">group A streptococcus</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
The basis of autoimmune processes that contribute to the development of RHD is T-cell molecular mimicry between streptococcal and heart proteins. RHD is initiated by certain serotypes connected with group A streptococcus M protein. Guilherme and colleagues suggest that M5 peptide causes severe RHD in patients who have HLA-DRB1*07 combined with severe RHD [53]. In our study, patients with severe RF who developed RHD in cases of MVR as well as MVL all had the DRB1*07 allele.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 797 805 <span type="species:ncbi:9606">patients</span>
Our findings indicate that the HLA class II alleles DQB1* and DRB1* are associated with a trend to risk/protection relating to RF and the development of RHD. HLA class II DRB1*07-DQB1*0401-2 and DRB1*07-DQB1*0302 can be considered to be risk genotypes, while HLA class II DRB1*06 and DQB1*0602-8 are probably protective. Considering the association of the HLA-DRB1 and DQB1 genotype with RHD risk/protection, patients with DRB1*07-DQB1*0401-2 are at risk of acquiring MVR, and DRB1*07-DQB1*0302 patients are at risk of acquiring MVL. By genotype analysis, we found that the RHD risk is increased in individuals with DRB1*01-DQB1*0301-DRB1*07-DQB1*0302 and DRB1*15-DQB1*0302-DRB1*07-DQB1*0303 genotypes. As we mentioned before, this conclusion is only a supposition, and study of a larger group of patients would be required to confirm it.
###end p 37
###begin p 38
The genotype DRB1*06-DQB1*0602-8 may be associated with protection against RF and the development of RHD.
###end p 38
###begin p 39
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 111 118 <span type="species:ncbi:9606">patient</span>
It is significant that the patients were grouped into clinically homogeneous groups as opposed to the total RF patient group, as the various subgroups differed in DQ allele frequencies.
###end p 39
###begin p 40
The severity of RF is probably associated with the DRB1*07 allele and development of certain RHD may be dependent on specific DQ alleles.
###end p 40
###begin p 41
###xml 280 288 <span type="species:ncbi:9606">patients</span>
Our study provides further information about the hypothesis that there is a genetic predisposition to RF and about the protective immune responses in RHD. Further insight into the molecular mechanisms of the disease will be a useful tool for predicting the clinical outcome in RF patients and may offer new means of and approaches to treatment and prophylaxis design in the future.
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
None declared.
###end p 43
###begin title 44
Abbreviations
###end title 44
###begin p 45
AVR = aortal valve regurgitation; MVL = multivalvular lesion; MVR = mitral valve regurgitation; OR = odds ratio; PCR-SSP = polymerase chain reaction with amplification with sequence-specific primers; PCR = polymerase chain reaction; RF = rheumatic fever; RHD = rheumatic heart disease.
###end p 45
###begin article-title 46
The Jones criteria for guidance in the diagnosis of rheumatic fever: another perspective
###end article-title 46
###begin article-title 47
Rheumatic fever
###end article-title 47
###begin article-title 48
Complications of streptococcal pharyngitis
###end article-title 48
###begin article-title 49
Global assessment of rheumatic fever and rheumatic heart disease at the close of the century: influences and dynamics of populations and pathogens: a failure to realize prevention?
###end article-title 49
###begin article-title 50
Group A streptococcal infections and acute rheumatic fever
###end article-title 50
###begin article-title 51
Genetic control of the suspectibility to infection with pathogenic bacteria
###end article-title 51
###begin article-title 52
Acute rheumatic fever
###end article-title 52
###begin article-title 53
Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease
###end article-title 53
###begin article-title 54
Long-term sequelae of the first attack of accute rheumatic fever during childhood
###end article-title 54
###begin article-title 55
HLAs and predisposition to the nonsuppurative sequelae of group A streptococcal infections
###end article-title 55
###begin article-title 56
The familial epidemiology of rheumatic fever: genetic and epidemiologic studies
###end article-title 56
###begin article-title 57
Pattern of hereditary susceptibility in rheumatic fever
###end article-title 57
###begin article-title 58
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody
###end article-title 58
###begin article-title 59
###xml 24 29 <span type="species:ncbi:9606">human</span>
Association of class II human histocompatibility leukocyte antigens with rheumatic fever
###end article-title 59
###begin article-title 60
HLA-DR typing and lymphocyte subset evaluation in rheumatic heart disease: a search for immune response factors
###end article-title 60
###begin article-title 61
###xml 40 48 <span type="species:ncbi:9606">patients</span>
HLA blood groups and secretor status in patients with established rheumatic heart disease
###end article-title 61
###begin article-title 62
A genetic marker for rheumatic heart disease
###end article-title 62
###begin article-title 63
###xml 38 46 <span type="species:ncbi:9606">patients</span>
HLA-A, B, DR and DQ antigens in black patients with severe chronic rheumatic heart disease
###end article-title 63
###begin article-title 64
###xml 72 80 <span type="species:ncbi:9606">patients</span>
HLA-DR/DQ antigens and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease
###end article-title 64
###begin article-title 65
###xml 15 20 <span type="species:ncbi:9606">human</span>
Association of human leukocyte class II antigens with rheumatic heart disease in Brazilian population
###end article-title 65
###begin article-title 66
HLA antigens in Turkish race with rheumatic heart disease
###end article-title 66
###begin article-title 67
HLA class II antigens in rheumatic fever: analysis of the DR locus by restriction fragment-length polymorphism and oligotyping
###end article-title 67
###begin article-title 68
Post streptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles
###end article-title 68
###begin article-title 69
###xml 19 27 <span type="species:ncbi:9606">children</span>
Rheumatic fever in children
###end article-title 69
###begin article-title 70
Association of HLA-DR7 with rheumatic fever in the Brazilian population
###end article-title 70
###begin article-title 71
###xml 116 124 <span type="species:ncbi:9606">patients</span>
HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients
###end article-title 71
###begin article-title 72
###xml 40 48 <span type="species:ncbi:9606">patients</span>
HLA-A, B, DR, and DQ antigens in Indian patients with severe chronic rheumatic heart disease
###end article-title 72
###begin article-title 73
###xml 32 40 <span type="species:ncbi:9606">patients</span>
HLA antigen pattern of Kashmiri patients with rheumatic heart disease
###end article-title 73
###begin article-title 74
HLA-DQA1 genes involved in genetic susceptibility to rheumatic fever and rheumatic heart disease in southern Hans [in Chinese]
###end article-title 74
###begin article-title 75
[The HLA-associated immunological mechanisms in rheumatic involvement of the myocardium. - in Russian]
###end article-title 75
###begin article-title 76
###xml 45 53 <span type="species:ncbi:9606">patients</span>
DNA typing of HLA class II genes in Japanese patients with rheumatic heart disease
###end article-title 76
###begin article-title 77
###xml 37 45 <span type="species:ncbi:9606">patients</span>
HLA class I and class II profiles of patients presenting with Sydenham's chorea
###end article-title 77
###begin article-title 78
Association of HLA class I and class II antigens with rheumatic fever in a Turkish population
###end article-title 78
###begin article-title 79
Immune response factors in Rheumatic heart disease: meta-analysis of HLA-DR associations and evaluation of additional class II alleles
###end article-title 79
###begin article-title 80
Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material
###end article-title 80
###begin article-title 81
Use of new variant HLA-DNA typing -mSSP at perspective selection of the donor of a nephros
###end article-title 81
###begin article-title 82
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
###end article-title 82
###begin article-title 83
HLA-DR, DQ and DT typing using PCR amplification and immobilized probes
###end article-title 83
###begin article-title 84
Preferential PCR amplification of alleles: mechanisms and solutions
###end article-title 84
###begin article-title 85
###xml 15 20 <span type="species:ncbi:9606">human</span>
Association of human leukocyte antigens in Thais with rheumatic heart disease
###end article-title 85
###begin article-title 86
DNA analysis of class II alleles in rheumatic disease in Mexicans [abstract]. 22nd Annual ASHI Meeting Abstracts
###end article-title 86
###begin article-title 87
###xml 26 34 <span type="species:ncbi:9606">Patients</span>
HLA Antigens in Brazilian Patients with Rheumatic Heart Disease
###end article-title 87
###begin article-title 88
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
HLA associated diseases. A summary of the 12th International Histocompatibility workshop component
###end article-title 88
###begin article-title 89
Infection and autoimmunity: a story of the host, the pathogen, and the copathogen
###end article-title 89
###begin article-title 90
A mechanism for the major histocompatibility complex-linked resistance to autoimmunity
###end article-title 90
###begin article-title 91
HLA and infection [review]
###end article-title 91
###begin article-title 92
Rheumatic fever pathogenesis
###end article-title 92
###begin article-title 93
Class II antigens and disease suspectibility
###end article-title 93
###begin article-title 94
Autoimune diseases: the failure of self tolerance
###end article-title 94
###begin article-title 95
Genetic control of the antibody response: relationship between immune responses and histocompatibility (H-2) type
###end article-title 95
###begin article-title 96
###xml 148 156 <span type="species:ncbi:9606">patients</span>
T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients
###end article-title 96
###begin title 97
Figures and Tables
###end title 97
###begin p 98
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Frequencies of DRB1* alleles in RF patients and healthy controls
###end p 98
###begin p 99
**Confield not accurate. Extract limits preferred. RF, rheumatic fever.
###end p 99
###begin p 100
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Frequencies of DQB1* alleles in RF patients and healthy controls
###end p 100
###begin p 101
**Confield not accurate. Extract limits preferred. RF, rheumatic fever.
###end p 101
###begin p 102
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Frequencies of DRB1 and DQB1 alleles in RF and RHD patients compared with control subjects
###end p 102
###begin p 103
###xml 174 175 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 225 227 223 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 236 238 234 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
Boldface type highlights statistically significant associations for patients vs controls. gf (gene frequency) P (probability), OR (odds ratio), and Mantel-Hanszel values (chi2) are reported only for significant associations (P < 0.05). n = number of haplotypes (e.g. 140 haplotypes from 70 individuals). The nature of valve lesions was not reported for two patients. MVL, multivalvular lesions; MVR, mitral valve regurgitation; RF, rheumatic fever; RHD, rheumatic heart disease.
###end p 103
###begin p 104
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Significant association of HLA-DRB1 genotypes with predisposition/protection in RF patients
###end p 104
###begin p 105
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Boldface type highlights statistically significant associations for patients vs controls. RF, rheumatic fever.
###end p 105
###begin p 106
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Significant association of HLA-DQB1 genotypes with predisposition/protection in RF patients
###end p 106
###begin p 107
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Boldface type highlights statistically significant associations for patients vs controls. RF, rheumatic fever.
###end p 107
###begin p 108
Summary of HLA alleles or genotypes associated with rheumatic heart disease
###end p 108
###begin p 109
An asterisk preceding the allele number indicates the allele molecular designation (typing at DNA level). Boldface type highlights association cross-validated in this study.
###end p 109

